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Abstract 
   
Ferritin is a key molecule in iron metabolism, as it stores the iron in a non-toxic form for the cells. Serum ferritin is a 
parameter that reflects the iron content of the body. However, serum ferritin is also an acute-phase reactant protein,  
as increased levels of serum ferritin are reported in many diseases associated with inflammation. Hyperferritinemia 
was also reported in COVID-19 (the coronavirus disease 19) patients, where it is considered an independent 
prognostic factor for the patients, indicating increased severity of the disease, risk for complications, and death. 
Certain categories of patients (older, those with comorbidities) have an increased risk of SARS-CoV-2 (severe acute 
respiratory syndrome coronavirus 2) infectivity and developing more severe forms of COVID-19. Chronic/acute 
systemic inflammatory states often characterize such preexisting comorbidities. In the current paper, a new pathogenic 
link is proposed and analyzed: between preexisting hyperferritinemia in the context of patient comorbidities (metabolic, 
cardiovascular, kidney, inflammatory, autoimmune, cancer) and the risk of SARS-CoV-2 infectivity and of developing 
more severe forms of infection. Ferritin per se can be a causal agent in COVID-19, as it can generate and aggravate 
inflammation and contributes to the development of a severe cytokine storm. A severe, uncontrolled inflammatory state 
occurs, triggered by the high levels of serum ferritin, preexisting comorbidities, and SARS-CoV-2 infection, cause of 
lethality in many patients. The inflammatory stimuli can further aggravate the infection by activating ADAM-17 
(disintegrin and metalloprotease 17), a key enzyme involved in ACE2 (angiotensin-converting enzyme 2) activation 
and viral infectivity. In this context, iron chelators and antioxidants could become potential lines of treatment in COVID-
19. 
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Ferritin functions and structural features  
Ferritin is a highly conserved molecule, present from 
prokaryotes to vertebrate organisms, first described in 1937 by 
Victor Laufberger and extracted from horse spleen [1-4]. It is a 
nanocage protein that is a key player in iron metabolism, as it 
stores iron in a non-toxic form for the cell [5, 6].  It is also 
essential for iron recycling depending on cellular needs. Iron is 
required for a vast array of processes and reactions, being able 
to act as a donor/receiver of electrons and intervening in various 
processes either as a cofactor or a catalyst: cell energy 
production, mitochondrial respiration, RNA and DNA 
synthesis, protein synthesis; it is essential for the production of 
the heme groups of hemoglobin and therefore for oxygen  
 
 
transport and cellular oxygenation; synthesis of other molecules 
similar to hemoglobin, such as myoglobin, cytochromes; iron-
dependent histone demethylases; various enzymes; formation of 
iron-sulfur clusters; cell survival and proliferation; prevention 
of oxidative damage (antioxidant role of ferritin) or, on the 
contrary, generation of free oxygen reactive species (free iron); 
immuno-modulatory functions [6-9]. Free iron is very toxic as it 
can accept or donate electrons to other molecules, leading to 
cellular damage; it also reacts with free oxygen radicals (Fenton 
and Haber-Weiss reactions) and leads to even more aggressive 
reactive oxygen species [8-11]. Therefore, iron metabolism, 
circulation, oxidation states, and storage must be very tightly 
regulated processes, impeding free iron toxicity and iron 
overload but allowing for an adequate release of iron for the 
cellular needs [12]. The classical, ubiquitously present ferritin 
comprises 24 subunits that self-assemble into an almost 
spherical cage with an external and internal diameter of 12 nm 
and 8 nm, respectively [1, 7]. Invertebrates, two types of ferritin 
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subunits assemble to form the ferritin molecule: L (light) and H 
(heavy) ferritins, genetically encoded on the 11q and 19q 
chromosomes in humans. The ratio of H/L–ferritin subunits is 
variable depending on the tissue, type of cell, cell 
subcompartment, metabolic rate, environmental factors, growth 
factors, translational and post-translational changes, and the 
presence of a large array of diseases [3, 4, 6, 8, 10, 13, 14]. The 
H-subunit has ferroxidase activity and plays the key role of 
oxidizing ferrous ions (Fe2+) to ferric ions (Fe3+) that can be 
further be stored in a mineralized, stable internal core of ferritin 
[6, 13]. Out of the multiple oxidation iron states (from -2 to +6), 
Fe3+ is the most stable, non-toxic iron state [7, 15]. The process 
of iron oxidation from Fe2+ to Fe3+ is therefore essential for 
the conversion of iron to a non-toxic form that can be stored 
inside of the cell; it is also important as it consumes free oxygen 
radicals in the process of iron oxidation that would otherwise 
accumulate and lead to cell damage [3, 8]. L-ferritin subunit 
lacks a ferroxidase activity; it has a salt bridge in its folds and 
therefore plays a role only in the stability of the ferritin cage 
and in the ferric iron storage [1, 13]. As the two subtypes of 
ferritin units have functional and structural differences, the ratio 
between the two in the ferritin nanocage differs between tissues, 
depending on the metabolic rate and need for a fast release of 
iron for incorporation into proteins. For example, in tissues 
characterized by high metabolic rates and the generation of a 
considerable amount of reactive oxygen species, such as the 
brain, heart, kidney, there is a predominant expression of the H-
ferritin in the ferritin nanocage. Instead, in tissues characterized 
by important iron storage, such as the liver and spleen, there is 
more L-ferritin than H-ferritin into the cells [3, 6, 9]. 
 
Types of ferritin  
There are three types of intracellular ferritin in humans: 
cytosolic, nuclear, and mitochondrial [9]. Nuclear ferritin forms 
H-subunits, while both L- and H-ferritins are present in the 
cytosol [6]. Mitochondrial ferritin is very similar to the H-
subunit ferritin, with a 79% homology between the two; it is 
expressed mainly in the tissues characterized by high metabolic 
rates, having a protective role against the oxidative stress, and 
being uncorrelated to the cellular iron content [1, 3]. Cellular 
ferritin synthesis is stimulated by high iron levels, oxidative 
stress, inflammatory stimuli/pathways. As H- and L- ferritin 
promoters have an antioxidant responsive element, ferritin 
synthesis is influenced by oxidative stress. Also, there is a 
hypoxia-responsive element in the 5'-promoter region of the 




Ferritin is also found in the serum and various liquids, such as 
cerebrospinal fluid, synovial fluid, and urine, being constituted 
only from L-subunits [3, 9]. Serum L-ferritin is one of the 
tiniest understood molecules, although it is a laboratory test 
more and more requested in clinical practice [10]. It is not 
known if it is a monomeric or multimeric structure, and its 
functions are of unclear significance yet. Although 
insufficiently ascertained, circulating L-ferritin would act as an 
iron deliverer for cells [9]. Despite the limitations regarding its 
knowledge, serum ferritin is considered a very valuable clinical 
parameter. It can provide information regarding the body's iron 
content and differentiate between iron-deficiency anemia and 
other causes of anemia [5, 6, 9, 10]. However, serum ferritin 
levels do not always correlate well with the iron organism 
levels, as they can be influenced by many factors and diseases 
[6, 9, 10, 16, 17]. Also, serum ferritin stores only a small 
amount of iron [4], and therefore its quantification offers only 
limited information in this regard. The sources of serum ferritin 
are non-classical pathways secretion out of the cells into the 
serum; and release into the serum as a result of cell damage and 
death [1, 9, 10, 18, 19]. Various stimuli, such as pro-
inflammatory cytokines (interleukin 1 (IL-1), interleukin 6 (IL-
6), interleukin 10 (IL-10), tumor necrosis factor-alpha (TNF-
alpha), and interferon-gamma (IFN-gamma) that act via NF-kB 
pathway), growth factor or hypoxia can lead to increased 
secretion of ferritin [9, 10]. One of the significant sources of 
ferritin is the macrophages, which secrete it along with other 
cytokines [6, 19]; another important source can be the 
hepatocytes [9, 10]. After macrophage release, serum ferritin is 
physiologically glycosylated to a necessary extent (50-80% of 
the serum ferritin); a lower or a higher level of glycosylation 
has been associated with various diseases [6, 10]. The normal 
serum ferritin range is up to 200 μg/L in females and up to 300 
μg/L in males [5, 10]. The serum ferritin appears to correlate 
well with the levels of intracellular ferritin, and high 
intracellular ferritin will be usually paralleled by 
hyperferritinemia. Hyperferritinemia can indicate a high level of 
iron or, maybe even more frequently, the presence of 
one/multiple diseases characterized by inflammatory states. A 
high level of iron is toxic [17] and determines an increase in 
ferritin generation via the iron regulatory proteins 1 and 2 (IRP 
1 and 2) acting on IRE (iron response elements) present at the 
5’UTR of the ferritin transcripts [1, 2, 10]. It was reported that 
inflammatory stimuli mainly induce an increase in H-ferritin 
level, while high iron levels of L-ferritin [9]. 
 
Increased serum ferritin levels in diseases 
Serum ferritin and intracellular ferritin have markedly increased 
levels in many inflammatory autoimmune diseases and acute 
phase reactions [10, 19, 20]. Such diseases that are 
characterized by chronic or acute inflammation, altered iron 
metabolism, and associate high serum ferritin levels include 
infections (acute, chronic, sepsis;  viral, such as influenza 
infection, HCV and HIV; bacterial (including tuberculosis); 
autoimmune diseases, such as rheumatoid arthritis, systemic 
erythematosus lupus; kidney diseases; cancer (breast, colorectal, 
non-small lung cancer, prostate, pancreatic, oral, ovarian, 
renal); metabolic diseases (diabetes mellitus, obesity, 
dyslipidemia); cardiovascular diseases including hypertension; 
neurodegenerative diseases, such as Parkinson, Alzheimer, 
multiple sclerosis [1, 2, 4, 10, 13, 16, 21-35]. The inflammatory 
state/chronic inflammatory microenvironment is considered a 
consequence, a trigger, and/or an aggravating factor for the 
diseases mentioned above, leading to increased patient 
morbidity and mortality rates and the development of other 
severe chronic diseases [30 36-39]. Older age and male patients 
usually have higher serum ferritin levels than younger and 
female counterparts [40-45]. An elevated serum ferritin level in 
such diseases is considered an inflammatory marker, an acute 
phase reactant. It can be used along with other markers (C-
reactive protein, procalcitonin, lactate dehydrogenase (LDH), 
fibrinogen, D-dimers, erythrocyte sedimentation rate (ESR), IL-
6, etc.) for a better interpretation of disease evolution. The 
significantly increased levels of serum ferritin seen in the 
mentioned diseases and states correlate very well with the 
severity degree of the disease. Therefore, serum ferritin levels 
can be used as prognostic markers for the disease evolution, risk 
of developing severe complications, and death [19, 20]. It was 
reported that a ferritin level higher than 200 μg/L is a clear 
indicator for an increased risk of mortality for the patients with 
the previously mentioned diseases, the most critical cumulative 
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risk being at ferritin levels higher than 600 μg/L [10]. Also, 
elevated serum ferritin levels can predict the development of 
such diseases that develop under chronic systemic pro-
inflammatory states [46-48]. Even a link between 
inflammation– metabolic syndrome- high serum ferritin levels 
and the risk of developing other diseases, such as 
cardiovascular, was reported [49, 50]. That is, ferritin level 
holds a prognostic significance. However, it is not known 
whether the high levels of serum ferritin seen in the multiple 
diseases mentioned above are a cause or a secondary 
consequence, nor if they can exhibit protecting or, on the 
contrary, aggravating effects in the course of a pathological 
process. It is not known whether there is an etiologic role for 
ferritin in the mentioned diseases [6, 10, 51]. Some studies 
report a pro-inflammatory effect of ferritin per se [10, 14, 16, 
51], while others consider that ferritin can act as a protective 
factor in specific pathologies (e.g., protective effects of H-
ferritin against acute kidney injury or vascular calcification) [1].  
The increase in the ferritin levels seen in the inflammatory 
states can initially represent a mechanism of protection against 
a dangerous external agent (virus, bacteria, fungi) or internal 
(abnormal, compromised, toxic structures, such as in 
autoimmune diseases, neurodegenerative diseases, metabolic 
diseases, cancer). Pathogens and cancer cells require high iron 
levels for their survival and multiplication; in the case of 
cancers, iron is also essential for epithelial to mesenchymal 
transition, migration, and metastasis [6]. In the scenario of 
infections, ferritin might be a protective molecule as it 
sequestrates into intracellular stores, preventing the iron from 
being used by the pathogenic agents [9]; also, it has an 
antioxidant role. At the same time, serum ferritin could display 
immune-modulatory or even immunosuppressive roles, limiting 
the detrimental uncontrolled inflammatory storm [2, 9, 51]. By 
its anti-apoptotic functions, ferritin might determine a chronic 
tolerance to infections like hepatitis C virus, malaria, 
mycobacteria, HIV, and even sepsis [1, 9]. In infections and 
ferritin, another player intervenes as well: hepcidin. Hepcidin, a 
relatively newly described molecule produced in the liver, 
physiologically prevents iron release from the cells via 
ferroportin; hepcidin also inhibits iron absorption by the 
enterocytes. Therefore, hepcidin also limits pathogens' iron 
access [4, 8, 10, 11]. However, the opposite, detrimental effect 
of deregulated hyperferritinemia is even more frequently 
reported as a pathogenic vicious circle of disease can occur. 
Ferritin can determine more inflammation, aggravating the 
infection [14]. More ferritin can release more free iron from the 
cells; high free iron signals for even more ferritin synthesis, 
oxidative stress, inflammation, and cellular damage; excess 
ferritin can lead to the generation of ferritin aggregates, as 
described in some genetic ferritin disorders [3]. Such a 
deregulated process has also been described in 
neurodegenerative diseases (Alzheimer, Parkinson), although it 
is unclear whether ferritin metabolism alteration is the etiologic 
agent or only a consequence of the disease. However, in 
infections, hepcidin production is increased, leading to 
pronounced sequestration of iron into the cells, especially into 
macrophages, aiming to deprive the pathogens of it [8, 12]. This 
explains a chronic inflammatory type of anemia in such chronic 
diseases [4, 8]. At the same time, important iron sequestration 
into the host cells (via increased intracellular ferritin and 
following hepcidin production) would potentially become toxic; 
the ferritin iron storage capacity is probably saturable, and upon 
iron saturation, ferritinophagy and ferritinoptosis will ensue; 
there will be freer iron into the cells, oxidative damage, and cell 
death.   
In cancer, more ferritin and intracellular iron stores have also 
been described. Iron is helpful for the cancer cells as it is a 
catalyst for the histone demethylation, a process required for 
epigenetic plasticity; also, more intracellular ferritin protects the 
cell from oxidative damage; otherwise, such significant 
oxidative stress could easily affect the cells characterized by 
high metabolic rates, as cancer cells [1, 6, 9]. Ferritin might be 
pro-oncogenic by promoting oxidative stress, followed by lipid 
peroxidation, DNA strand damage, mutagenesis [4,10]. 
However, elevated ferritin levels can activate pro-inflammatory 
macrophages associated with cancer cells that appear to 
function for cancer progression [6, 9]. 
 
Ferritin- a link between various comorbidities and COVID-
19  
A recent observation is that in COVID-19 infection, there are 
increased levels of serum ferritin (hyperferritinemia, that is 
more than 300 μg ferritin/L), along with other pro-inflammatory 
markers (IL-1, IL-6, TNF-alpha, IFN-gamma, D-dimers, LDH, 
procalcitonin, C-reactive protein). In fact, a 3 to 4 times higher 
serum ferritin level was reported in the COVID-19 non-
survivors [2, 6, 16, 19, 51]. Also, higher serum ferritin levels 
were reported in patients with thrombotic complications than in 
the others [16]. Hyperferritinemia correlates well with the 
severity of the COVID-19, and the serum ferritin levels increase 
during the aggravation of the infection [19, 52]. Therefore, high 
serum ferritin levels indicate a very severe infection and poor 
prognosis, predicting the development of life-threatening 
complications, such as respiratory failure, organ dysfunction, 
need for ICU hospitalization, and death [11, 14, 16, 19, 20]. 
Interestingly, serum ferritin levels begin to decrease when the 
COVID-19 patients’ state begins to ameliorate [51]. Actually, 
ferritin levels are considered an independent prognostic factor 
for COVID-19 patients [19]. Also, ferritin levels have been 
proposed as a marker of viral replication [16]. It is already 
ascertained that specific categories of patients have a higher risk 
of SARS-CoV-2 infectivity and developing more aggressive, 
severe forms of COVID-19. Such categories are older, male 
patients; also patients with preexisting comorbidities such as 
hypertension, cardiovascular diseases; metabolic diseases 
(diabetes mellitus, obesity, dyslipidemia, and steatosis); kidney 
diseases; cancer; inflammatory and autoimmune diseases [1, 16, 
19, 29, 53-58]. Until now, no apparent, final, and unanimous 
explanation was found regarding the mechanisms behind such 
vulnerability for the SARS-CoV-2 severe infections in the 
categories mentioned above of patients. As ACE2 are the 
receptors for the SARS-CoV-2 [59], a temporary hypothesis 
was a higher expression of ACE2 receptors in such diseases, 
male patients, and older age, increasing the risk and severity of 
SARS-CoV-2 infection [53, 60-65]. However, this hypothesis 
was not validated afterward. For example, children have higher 
levels of whole-membrane ACE2 receptors, but instead, they 
have a low risk of infectivity or of developing symptomatic or 
severe forms of COVID-19. Usually, if they are infected, they 
develop asymptomatic/oligosymptomatic mild forms of 
infection, and only children with preexisting severe 
comorbidities can present more severe forms of the disease 
[66]. The explanation, therefore, could come not from a higher 
expression of ACE2 receptors but their hyperferritinemia status, 
cause and/or consequence, as well as a contributor to their 
chronic inflammatory states. There is already a report where the 
authors consider a link between inflammation, cancer, and more 
severe forms of SARS-CoV-2 infection [29].  
In this context, we hypothesize a causal link between 
preexisting elevated serum ferritin levels due to various patient 
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comorbidities (that associate an inflammatory state and 
oxidative stress) and a higher risk of SARS-CoV-2 infectivity 
of developing more severe forms of infection. The 
chronic/acute inflammation reported in such diseases sustained 
by hyperferritinemia creates a vulnerable status for other 
infections, including SARS-CoV-2 infection. Such a 
vulnerability fueled by the preexisting immune dysregulation 
and severe pro-inflammatory status [16] can more rapidly 
trigger a veritable cytokine storm. It is ascertained that the 
inflammatory states, via cytokines and chemokines, determine 
an upregulation of ferritin expression with the accumulation of 
more and more ferritin into the cells [14]. Pro-inflammatory 
cytokines such as IL-1, IL-6, IL-10, TNF-alpha, and IFN-
gamma, massively produced in COVID-19 as well, will 
therefore increase ferritin levels [1, 10, 20, 51]. It appears that 
once produced in excess; ferritin will feed a positive feedback 
loop, determining more inflammation, the generation of more 
pro-inflammatory cytokines, and the activation of M1 
macrophages [51]. Ferritin (H-ferritin) was reported to activate 
M1 macrophages, production of cytokines, leading to 
inflammation and even pyroptotic cell death [14,16]; it 
regulates many intracellular signaling pathways, such as pro-
inflammatory pathways, with the activation of the NF-kB 
(nuclear factor kappa-B) that leads to more inflammation; it 
also regulates c-Jun N-terminal kinase (JNK) pathway (ferritin 
inhibits it, preventing cell apoptosis and promoting survival); 
ERK pathway, MAPK-pathway, and others [3, 4, 6, 9]. It has 
also been reported that ferritin can directly, at the nuclear level, 
stimulate the gene expression of several pro-inflammatory 
cytokines, such as IL-1 beta, IL-6, TNF-alpha, and others [9, 
19]. The excessively produced inflammatory mediators will 
stimulate ferritinophagy, with increased intracellular free iron, 
leading to oxidative stress, lipid peroxidation, and ferroptosis 
[2, 6]. Ferroptosis is an iron-regulated form of cell death [3]. 
Ferroptosis will promote inflammation, oxidative stress, and 
cell damage [9, 11]. COVID-19 itself is also a disease that is 
characterized by an exaggerated uncontrolled systemic 
inflammation and cytokine storm, similar to the macrophage 
activation syndrome, leading to organ dysfunction and damage, 
increased infection severity, and mortality [2, 11, 16, 19, 20, 58, 
67-70]. Therefore, a positive feedback loop of inflammation 
triggered by preexisting high ferritin levels [14] (in the context 
of diseases associated with chronic inflammatory states) could 
be detrimental for sure. Systemic inflammation with 
uncontrolled cytokine storm is recognized as a cause of 
mortality in COVID-19 patients [6, 14, 51]. In infections like 
COVID-19, cell damage by the viruses is another source of 
ferritin release into the serum, as reported in liver diseases. As 
ferritin assembly is dependent on environmental factors, 
including pH, ferritin molecules will be able to disassemble into 
the serum, releasing toxic free iron that will determine oxidative 
stress, more inflammation, cytokine storm, and cellular damage, 
leading to multiple organ dysfunction and even death [10, 11]. 
The SARS-CoV-2 virus also attacks hemoglobin, releasing 
toxic free iron, leading to oxidative stress and inflammation. 
The inflammatory state will determine more ferritin being 
produced [4]; in fact, a vicious, positive feedback loop is 
described between cytokines and ferritin [19]. The released free 
iron, the result of the hemoglobin attack by the virus, will also 
stimulate ferritin production; the result will be more 
inflammation and a pro-thrombotic state (free iron determines 
fibrinogen conversion to fibrin) [11]. SARS-CoV-2 can also 
mimic hepcidin, leading to increased ferritin levels and further 
inflammation [11]. 
Therefore, as ferritin per se can also lead to/aggravate 
inflammation [9, 14], it could be a key player in COVID-19 
pathogenesis. The cytokine storm and ferritin lead to acute 
respiratory distress syndrome (ARDS) [16]. In this context, 
there are reports after postmortem analysis that SARS-CoV-2 
does not determine pneumonia or ARDS per se; instead, free 
iron leads to oxidative damage, inflammation, and cellular and 
organ damage [11]. That could be the explanation why in 
COVID-19 patients, extremely high levels of serum ferritins 
(that signal or even trigger inflammation) were observed in 
severe forms of infection, along with the occurrence of 
complications and correlated with a poor prognostic and 
survival. Additional mechanisms to explain why a preexisting 
inflammatory status (as reported in patients with essential 
comorbidities) has an increased risk of SARS-CoV-2 infection 
could intervene. Inflammatory stimuli and reactive oxygen 
species (the result of increased levels of iron released from 
cells) lead to an activation of key enzymes for viral infectivities, 
such as ADAM-17 or even of ACE2, that could intervene as an 
activating enzyme for the SARS-CoV-2 as well, as 
hypothesized in a recent study [71-74]. ADAM-17, also known 
as TACE, is known to activate membrane ACE2, a process 
important for viral infectivity; also, it can act as an activator 
enzyme for the SARS-CoV-2 as well, with putative cleavage of 




In this context, considering that ferritin is one of the least 
understood molecules in disease, more research would be 
needed: to establish whether ferritin can act as a triggering 
factor for infections and other diseases or whether its increased 
levels are only a consequence. In this concern, international, 
large-scale multicentric research should be performed to link 
the serum ferritin and iron levels in various diseases and the risk 
of SARS-CoV-2 infectivity/risk of developing more severe 
forms of infection. However, such research is hindered by the 
difficulties in iron quantification in the serum and at 
intercellular levels. Also, more in vitro studies should be 
performed; macrophages and other cells, in various 
environmental conditions, should be exposed to different 
ferritin levels/ different types of ferritins, and the levels and 
types of released cytokines are measured afterward. In COVID-
19, a new question should be raised supplementary: whether 
ferritin does not indirectly/directly affect the expression and 
functionality of the membrane ACE2 receptors. This question 
appears of significance as in severe COVID-19 patients, 
hyperferritinemia (along with other serum pro-inflammatory 
markers) can be seen but paralleled by an increase in the serum 
enzymatic activity of ACE2 [52]. Understanding the 
hyperferritinemia significance in COVID-19 patients with 
significant comorbidities gains considerable significance. Such 
an understanding would be useful in designing prevention 
strategies for the patients' categories at increased risk of severe 
forms of disease and in treating such patients more efficiently. 
At the same time, the design and implementation of specific 
preventive strategies for the patients at risk are essential, as it 
was shown that we could not control pandemics only through 
measures of isolation and quarantine, especially when dealing 
with a virus that can reappear in successive waves across the 
globe, due to its impressive registry of mutations [75-78]. 
Suppose we accept the ferritin causal roles in infections like 
COVID-19. In that case, we could intervene with iron chelators 
(deferoxamine, deferasirox, deferiprone, or the natural 
lactoferrin) and antioxidants at the initial stages/in the course of 
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the infection to limit the progress and the severity of the 
disease.  Some authors already propose an attitude to fight 
cancer progression and severe infections, such as AIDS and 
COVID-19 [9-11]. In COVID-19, iron chelators could even 
prevent the SARS-CoV-2 from binding to its cellular receptors, 
as described by some authors [11].  One explanation for this 
effect could be that the iron chelators bind the virus; the other is 
that the chelators bind the viral membrane receptors. Also, 
lactoferrin binds to heparan sulfate proteoglycans that appear 
essential for SARS-CoV-2 binding to the ACE2 receptors. It 
appears that lactoferrin could also repress intracellular viral 
replication (11). We could also exploit the bio-ferritin 
nanocages to deliver enhanced therapies for COVID-19 
patients, as envisioned already for cancer therapy [6]. Such an 
example would be Artemisia-derived drugs, used to treat 
malaria and considered in treating SARS-CoV-2 infected 
patients. Artesunate can increase the lysosomal degradation of 
intracellular ferritin with the release of free iron and oxidative 
stress, leading to the death of the infected cells (therapeutic 
induction of ferroptosis) [6, 79, 80]. Therefore, there is a clear 
need for more research to enable knowledge on the exact link 
between preexisting patient comorbidities, serum ferritin levels, 
and COVID-19. Such a discovery would make possible a better 
prediction and prevention of SARS-CoV-2 infectivity, based on 
a clinically generally available determination of serum ferritin 
levels. A single aspect regarding ferritin and disease can be 
ascertained for now: nothing is for sure yet. Until better 
knowledge is achieved, valuable information, however, 
emerges: the usefulness of ferritin levels in predicting the 
course of COVID-19 and other diseases. 
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